A major clinical trial has found that low-dose interleukin-2 (IL2LD) is safe and may significantly extend survival in people with motor neurone disease (ALS).
Diabetic retinopathy is the real medical term for diabetic eye disease. It is the most common cause of blindness in people of working age. 94 million people are affected worldwide.
Digital biomarker can identify which cases of mild cognitive impairment will develop into Alzheimer’s so that early interventions can be put in place to prevent the onset of the disease.
Tara M. DeSilva from the Department of Neurosciences, Cleveland Clinic, walks us through regenerative therapies for multiple sclerosis, including comment on clues from studying normal brain development.
One of JPND’s key objectives is to fortify its work in brain health partnerships in Europe to better combat the challenges of neurodegenerative disease (ND).
Dr Roger J. Young, Professor at Saba University School of Medicine, walks us through Brittle Bone Disease, otherwise known as Osteogenesis Imperfecta Type I.
Advancing neuroscience research improves quality of life for all people with neurological disorders, and ultimately can prevent or cure these diseases. Open Access Government highlight some research priorities in neuroscience.
Jacqueline Hoogendam, JPND’s newly elected Vice-Chair and Executive Board member talks about JPND’s past and present strategies in its outreach campaign within and beyond Europe.
